Loading...
U.S. exports of biological products (except diagnostic) (NAICS 325414) totaled $5.3B in July 2026.
Importers of Biological Products (Except Diagnostic) paid $471K in duties in July 2026 — an effective duty rate of 10% on $4.7M in dutiable value, based on actual customs collections rather than the published tariff schedule. Biological Products (Except Diagnostic) imports of $3.3B in July 2026 ran 36% above the year-to-date monthly average of $2.4B.
Last updated: July 2026 dataNon-diagnostic biological products — including vaccines, blood-derived products, therapeutic proteins, monoclonal antibodies, and gene therapy products — are regulated by FDA's Center for Biologics Evaluation and Research (CBER) or Center for Drug Evaluation and Research (CDER) depending on product type, and require a Biologics License Application (BLA) for US marketing authorization. These products are among the most complex to import, combining stringent cold-chain requirements, lot-release testing, and facility licensure obligations that apply to both domestic and foreign manufacturers. Supply chains for biologics are highly specialized, and any deviation in storage or handling during transit can render a shipment inadmissible. Trade professionals should coordinate closely with FDA-licensed importers and qualified persons responsible for lot release.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
5.3K shipments/mo
For many biological products, FDA requires lot-by-lot release testing — either by FDA itself or by the manufacturer under an approved protocol — before the product can be distributed in the US. The BLA holder or licensed importer is responsible for ensuring that each lot meets release specifications and that required documentation accompanies the shipment. Failure to comply can result in detention or refusal of the entire lot.
Biologics are highly sensitive to temperature excursions, and documented cold-chain failures during transit can render a shipment inadmissible or require quarantine pending investigation. Importers must maintain continuous temperature monitoring records from the point of manufacture through port of entry, and FDA may request these records during admissibility review. Robust cold-chain qualification of carriers and freight forwarders is a critical risk-management step.
NAICSSector 32
National industry 3 of 4 in naics industry 32541
National industry 325414 · $3.3B of $15.9B
Supplier Network
Get discovered by U.S. importers searching for HS 325414 — Biological Products (Except Diagnostic). Be the first supplier listed.
Exports · July 2026
destination
customs district
Census does not publish district detail for this classification system.
origin
None recorded for this period.
entry
Census does not publish port detail for this classification system.
ImportsExports
Imports
$3.3BYoY · Pro
Exports
$5.3BYoY · Pro
12-mo low · imports
YoY · ProThrough July 2026. Source: U.S. Census Bureau.